Ryanodex Approval History
- FDA approved: Yes (First approved July 22nd, 2014)
- Brand name: Ryanodex
- Generic name: dantrolene
- Dosage form: Injectable Suspension
- Company: Eagle Pharmaceuticals, Inc.
- Treatment for: Malignant Hyperthermia
Ryanodex (dantrolene) is a skeletal muscle relaxant in a concentrated formulation for the treatment of malignant hyperthermia.
Development History and FDA Approval Process for Ryanodex
|Jul 23, 2014||FDA Approves Ryanodex for the Treatment of Malignant Hyperthermia|
|Mar 20, 2014||NDA for Orphan Drug Ryanodex Accepted By FDA|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.